Principal SAS Programmer

a highly motivated Principal SAS Programmer for our Development department.

• Develop and validate SDTM, ADaM, and Tables, Figures and Listings (TFLs) for Phase 1–3 studies, Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE)
• Prepare dataset specifications, define.xml files, and reviewer guides
• Create patient profiles and Data Management listings
• Build internal tools for standard reporting
• Ensure ongoing filing of study documentation and data in Basilea’s document management system
• Adhere to departmental policies and procedures
• Deliver high quality statistical reporting and data management services in a timely manner

• Master Degree in Biostatistics, Programming or Computational Sciences or equivalent
• Minimum 10 years relevant experience in SAS programming for clinical trials, experience in anti-infectives would be an asset
• Expert experience and skills in the use of SAS for development and validation of SDTM, ADaM and TFLs. Expert in SAS Stats, Graph and Macro
• Ability to work both independently and collaboratively in a team environment and to positively resolve conflicts, to write clear and concise technical reports and other business correspondence
• Well-organized and structured with excellent analytical skills and attention to detail
• Proactive personality with hands-on working experience
• Fluent in English, spoken and written, any other language is considered beneficial

Basilea is committed to putting people first. In addition to competitive remuneration, we offer the opportunity to work on inspiring, cross-functional projects in an engaging working environment. We strongly believe that every employee can make an impact and is vital to our success.

If you wish to become part of a company that strives to make a difference to the lives of patients worldwide, we are looking forward to receiving your application via our careers portal.

Additional information can be found on our website

Basilea is a commercial‑stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. Basilea has about 150 employees. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands, Cresemba® for the treatment of invasive fungal infections and Zevtera® for the treatment of bacterial infections.

In addition, we have preclinical anti‑infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN).